Lifecore Biomedical, Inc. Common Stock (LFCR)
Lifecore Biomedical, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of advanced biomaterials, including hyaluronic acid-based products used in medical and aesthetic applications. Founded in 1983, the company serves sectors such as ophthalmology, orthopedics, and aesthetics, providing products that support tissue repair and regeneration.
Company News
Lifecore Biomedical will participate in three pharmaceutical industry conferences in October and November 2025, including PODD, CPHI Worldwide, and American Pharma Manufacturing & Outsourcing Summit, where they will host booth meetings and participate in panel discussions.
U.S. stock futures were higher on Friday, with the S&P 500 and Nasdaq Composite indices slipping in the previous session. Tesla, Bumble, and Lifecore Biomedical were in focus.
Lifecore (LFCR) ends a year-long strategic review and will continue its operations on a stand-alone basis. The company also names a new CEO effective from May 20.
We've compiled a list of June Investment Picks that you may have missed. The investment ideas featured here are from Analysts who made no previous Buy recommendations in Q2.
Shares of Lifecore Biomedical on Monday climbed 19% to $6.40 in after-hours trading after the company said it secured a new $150 million financing agreement with its long-term customer Alcon.